Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
663
datasets available to search
ShareScore release 0.9.0
Dataset results
663 results for “Statins”
GWAS Summary Statistics from "Sex and statin-related genetic associations at the PCSK9 gene locus – results of genome-wide association meta-analysis"
<p>GWAMA summary statistics of PCSK9 levels stratified by sex and statin useage in Europeans.</p> <p>When using this data, please cite:</p> <p>Pott, J., Kheirkhah, A., Gadin, J.R. <em>et al.</em> Sex and statin-related genetic associations at the <em>PCSK9</em> gene locus: results of genome-wide association meta-analysis. <em>Biol Sex Differ</em> <strong>15</strong>, 26 (2024). https://doi.org/10.1186/s13293-024-00602-6</p> <p>All txt files contain the following columns:</p> <ul> <li>markername (unique SNP ID)</li> <li>chr</li> <li>bp_hg19 (base position according to hg19)</li> <li>EA (effect allele)</li> <li>OA (other allele)</li> <li>EAF (effect allele frequency)</li> <li>info (minimal info score across all used studies)</li> <li>nSamples (sample size per SNP)</li> <li>nStudies (in case of double-stratified data: number of studies; in case of single-stratified data: 2, as it is a meta-analysis of the two double-stratified data sets)</li> <li>beta (effect estimate)</li> <li>SE (standard error)</li> <li>pval (p-value)</li> <li>I2 (SNP heterogeneity across studies)</li> <li>invalidAssoc (TRUE/FALSE flag if this variant was excluded in our analysis)</li> <li>reason4exclusion (reason why this SNP was excluded)</li> <li>phenotype (phenotyp setting)</li> </ul>
S44 | STATINS | Statins Collection from Public Resources
<p>This is the collection associated with list S44 STATINS on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/?q=suspect-list-exchange">https://www.norman-network.com/?q=suspect-list-exchange</a></p> <p>S44</p> <p>STATINS</p> <p><strong>S</strong><strong>tatins Collection from Public Resources</strong></p> <p>STATINS <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/120219Update/STATINS_14022019.xlsx">XLSX</a>, <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/120219Update/STATINS_14022019.csv">CSV</a> (14/02/2019)<br> CompTox <a href="https://comptox.epa.gov/dashboard/chemical_lists/statins">STATINS List</a></p> <p>STATINS <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/120219Update/STATINS_InChIKeys_14022019.txt">InChIKeys</a> (14/02/2019)</p> <p>A list of statins (lipid-lowering medications) compiled from public resources, details on CompTox. </p>
Atomic resolution X-ray diffraction images for endothiapepsin complexed with a cyclic statine inhibitor.
<p>X-ray diffraction images for endothiapepsin complexed with inhibitor CP-129,541. The data were collected on 29th April 2001. </p>
A BCT Intervention for Physical Activity Among Individuals on Statins
ClinicalTrials.gov study NCT05273723. IPD Sharing: YES. Countries: 1. Publications: 2.
Statin therapy inhibits fatty acid synthase via dynamic protein modifications
<p>Statins are a class of drugs widely prescribed to prevent cardiovascular disease, with pleiotropic cellular effects. Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate. Recent discoveries revealed HMG-CoA is a reactive metabolite that can non-enzymatically modify proteins and impact their activity. Therefore, we predicted that inhibition of HMGCR by statins might increase HMG-CoA levels and protein modifications. We observed a substantial increase in HMG-CoA levels upon statin treatment, and only a single protein was modified. Mass spectrometry revealed fatty acid synthase (FAS) was modified on active site residues, and surprisingly, the modification is located on non-lysine side-chains. The dynamic modifications occur only on a sub-pool of FAS near HMGCR and alter cellular signaling around the ER and Golgi. These results uncover communication between cholesterol and lipid biosynthesis by the substrate of one pathway inhibiting another in a rapid and reversible manner. </p>
Raw data for optimization and calibration of Micellar liquid chromatography as a sustainable tool to quantify three statins in oral solid dosage forms
<p>A method based on micellar liquid chromatography has been developed to determine rosuvastatin, lovas- tatin and simvastatin in oral solid dosage forms. Samples were solved in mobile phase up to the target concentration, filtered and directly injected. The three statins were resolved in 30 min, using an aqueous solution of 0.10 M sodium dodecyl sulfate –7.0% 1-butanol, buffered at pH 3 with 0.01 M phosphate salt as mobile phase, running under isocratic mode at 1 mL/min through a C 18 column. Detection was at 240 nm. The effect of sodium dodecyl sulfate on elution strength was more important than that of the organic solvent. The procedure was successfully validated by the guidelines of the International Coun- cil for Harmonization in terms of: specificity, linearity ( r 2 > 0.990), calibration range (1.5 - 15 mg/L for rosuvastatin, 0.5–10 mg/L for lovastatin and simvastatin), limit of detection (0.4, 0.2 and 0.15 mg/L for ro- suvastatin, lovastatin and simvastatin, respectively), trueness (98.8–101.7%), precision ( < 2.7%), carry-over effect, robustness, and stability. Values were inside the acceptance criteria of the Methods, Method Veri- fication and Validation, Food and Drug Administration-Office of Regulatory Affairs, thus ensuring the re- liability of the results. The main feature was the low proportion of organic solvent used, thus making the procedure sustainable and green. Besides, it was easy-to-conduct and with high sample-throughput, and then useful for routine analysis in pharmaceutical quality control. Finally, it was applied to commercial pharmaceutical preparations.</p>
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
ClinicalTrials.gov study NCT00939822. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Pragmatic, Randomized Evaluation of Statin Active Choice to Reach Improved Outcomes Based on Evidence
ClinicalTrials.gov study NCT03021759. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Quality Improvement and Personalization for Statins
ClinicalTrials.gov study NCT02820870. IPD Sharing: NO. Countries: 1. Publications: 1.
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
ClinicalTrials.gov study NCT01236365. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Statin Therapy in Young Adult Survivors of Childhood Cancer
ClinicalTrials.gov study NCT01733953. IPD Sharing: NO. Countries: 1. Publications: 1.
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
ClinicalTrials.gov study NCT01047501. IPD Sharing: NO. Countries: 1. Publications: 13.
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
ClinicalTrials.gov study NCT02437084. IPD Sharing: NO. Countries: 1. Publications: 20.
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
ClinicalTrials.gov study NCT00166036. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
ClinicalTrials.gov study NCT02715726. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Exercise, Statins, and the Metabolic Syndrome
ClinicalTrials.gov study NCT01700530. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
ClinicalTrials.gov study NCT02135029. IPD Sharing: Not stated. Countries: 2. Publications: 2.
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
ClinicalTrials.gov study NCT01763866. IPD Sharing: Not stated. Countries: 21. Publications: 12.
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
ClinicalTrials.gov study NCT01375764. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
ClinicalTrials.gov study NCT01709513. IPD Sharing: Not stated. Countries: 8. Publications: 7.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.